Mark S. Shearman, Ph.D.
Chief Executive Officer
- Chief Scientific Officer/Executive Vice-President, Editas Medicine
- Chief Scientific Officer, Applied Genetic Technologies Corporation
- Senior Vice-President, Neurology, EMD Serono
- Executive Director, Neuroscience, Merck & Co.
- Senior Director, Neuroscience, Merck Sharp & Dohme, UK
- Post-doctoral research fellowships at Max-Planck Institute for Biochemistry, Germany and Kobe University School of Medicine, Japan
- D. Neuroscience, University of Nottingham, UK
- Sc.(Hons) University of Bristol, UK
- CNS drug discovery, cell and gene therapy, gene editing
- Neurodegenerative diseases, Multiple Sclerosis, Ophthalmology, Immuno-Oncology, Sickle-cell disease